BridgeBio Calls Off Its Acquisition Offer for Eidos Therapeutics
BridgeBio announced this week that it had terminated its effort to acquire the remaining stake in subsidiary Eidos Therapeutics. What does this mean for Eidos shareholders?
BridgeBio Pharma Inc
BBIO
BBIO
$36.44
-$1.01
-2.7%
BATS BZX Real Time Price as of December 13, 2019, 3:53 p.m. EST
View Interactive BBIO Charts
News & Analysis: BridgeBio Pharma Inc
Are There Good Investments Among 2019's Biotech IPOs?
Investing in biotechs is inherently risky. IPOs are too. What does the stock performance of 2019’s biotech IPO class look like so far?
3 Top Biotech Stocks to Buy in October
These small-cap biotechs have fallen to bargain prices.
2 Small-Cap Biotechs With Huge Upside
These innovative healthcare companies promise investors a way to benefit from medical breakthroughs without the usual risk.
2 New Healthcare Stocks That Wall Street Thinks You Should Buy
This pair of healthcare businesses made their public debut in June, but they're already making a big impression.
